Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Sapna Patel
SWOG Cancer Research Network
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
576 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Bcca-Vancouver Cancer Centre
Vancouver, British Columbia, Canada
- the Vitalite Health Network - Dr Leon Richard Oncology Centre
Moncton, New Brunswick, Canada
- Royal Victoria Regional Health Centre
Barrie, Ontario, Canada
- Juravinski Cancer Centre at Hamilton Health Sciences
Hamilton, Ontario, Canada
- Kingston Health Sciences Centre
Kingston, Ontario, Canada
- Waterloo Regional Health Network
Kitchener, Ontario, Canada
- London Regional Cancer Program
London, Ontario, Canada
- Trillium Health Partners - Credit Valley Hospital
Mississauga, Ontario, Canada
- Lakeridge Health Oshawa
Oshawa, Ontario, Canada
- Ottawa Hospital and Cancer Center-General Campus
Ottawa, Ontario, Canada
- Algoma District Cancer Program Sault Area Hospital
Sault Ste. Marie, Ontario, Canada
- Thunder Bay Regional Health Science Centre
Thunder Bay, Ontario, Canada
- Odette Cancer Centre- Sunnybrook Health Sciences Centre
Toronto, Ontario, Canada
- University Health Network-Princess Margaret Hospital
Toronto, Ontario, Canada
- Windsor Regional Cancer Centre
Windsor, Ontario, Canada
- Hopital de la Cite-de-la-Sante
Laval, Quebec, Canada
- the Research Institute of the Mcgill University Health Centre (muhc)
Montreal, Quebec, Canada
- Chu de Quebec-L'Hotel-Dieu de Quebec (hdq)
Québec, Quebec, Canada
- Centre Hospitalier Universitaire de Sherbrooke-Fleurimont
Sherbrooke, Quebec, Canada
- Allan Blair Cancer Centre
Regina, Saskatchewan, Canada
- Saskatoon Cancer Centre
Saskatoon, Saskatchewan, Canada
- Saint Vincent'S University Hospital
Dublin, Co Dublin, Ireland
- University College Hospital Galway
Galway, Co Galway, Ireland
- University Hospital Waterford
Waterford, Co Waterford, Ireland
- University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States
- Cancer Center at Saint Joseph'S
Phoenix, Arizona, United States
- Virginia G Piper Cancer Care-del Camino
Scottsdale, Arizona, United States
- Banner University Medical Center - Tucson
Tucson, Arizona, United States
- University of Arizona Cancer Center-North Campus
Tucson, Arizona, United States
- University of Arkansas for Medical Sciences
Little Rock, Arkansas, United States
- Highlands Oncology Group - Rogers
Rogers, Arkansas, United States
- Kaiser Permanente-Anaheim
Anaheim, California, United States
- Sutter Auburn Faith Hospital
Auburn, California, United States
- Kaiser Permanente-Baldwin Park
Baldwin Park, California, United States
- Kaiser Permanente-Bellflower
Bellflower, California, United States
- Uc Irvine Health Cancer Center-Newport
Costa Mesa, California, United States
- City of Hope Comprehensive Cancer Center
Duarte, California, United States
- Kaiser Permanente-Fontana
Fontana, California, United States
- Kaiser Permanente-Fremont
Fremont, California, United States
- Palo Alto Medical Foundation-Fremont
Fremont, California, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 10 Nov 2015
- Primary completion
- 15 Sept 2023
- Completion
- 23 Jan 2027
- Last update posted
- 2 Jul 2026
- Registered enrollment
- 1,301
- Registry id
- NCT02506153
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.